Switch theme
Sign up to access all valuation multiples
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
2006
824
LTM Revenue $458M
LTM EBITDA $96.1M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Veracyte has a last 12-month revenue of $458M and a last 12-month EBITDA of $96.1M.
In the most recent fiscal year, Veracyte achieved revenue of $446M and an EBITDA of $49.2M.
Veracyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Veracyte valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $361M | $446M | XXX | XXX | XXX |
| Gross Profit | $195M | $248M | XXX | XXX | XXX |
| Gross Margin | 54% | 56% | XXX | XXX | XXX |
| EBITDA | -$49.4M | $49.2M | XXX | XXX | XXX |
| EBITDA Margin | -14% | 11% | XXX | XXX | XXX |
| Net Profit | -$36.6M | -$74.4M | XXX | XXX | XXX |
| Net Margin | -10% | -17% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Veracyte's stock price is $32.
Veracyte has current market cap of $2.5B, and EV of $2.3B.
See Veracyte trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.5B | XXX | XXX | XXX | XXX | $0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Veracyte has market cap of $2.5B and EV of $2.3B.
Veracyte's trades at 4.9x LTM EV/Revenue multiple, and 23.6x LTM EBITDA.
Analysts estimate Veracyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Veracyte and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 46.1x | XXX | XXX | XXX |
| P/E | 103.8x | XXX | XXX | XXX |
| P/E/Growth | 1.9x | XXX | XXX | XXX |
| EV/FCF | 35.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVeracyte's NTM/LTM revenue growth is 10%
Veracyte's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Veracyte's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Veracyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Veracyte and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -200% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 62% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Veracyte acquired XXX companies to date.
Last acquisition by Veracyte was XXXXXXXX, XXXXX XXXXX XXXXXX . Veracyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Veracyte founded? | Veracyte was founded in 2006. |
| Where is Veracyte headquartered? | Veracyte is headquartered in United States of America. |
| How many employees does Veracyte have? | As of today, Veracyte has 824 employees. |
| Who is the CEO of Veracyte? | Veracyte's CEO is Mr. Marc A. Stapley. |
| Is Veracyte publicy listed? | Yes, Veracyte is a public company listed on NAS. |
| What is the stock symbol of Veracyte? | Veracyte trades under VCYT ticker. |
| When did Veracyte go public? | Veracyte went public in 2013. |
| Who are competitors of Veracyte? | Similar companies to Veracyte include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Veracyte? | Veracyte's current market cap is $2.5B |
| What is the current revenue of Veracyte? | Veracyte's last 12-month revenue is $458M. |
| What is the current EBITDA of Veracyte? | Veracyte's last 12-month EBITDA is $96.1M. |
| What is the current EV/Revenue multiple of Veracyte? | Current revenue multiple of Veracyte is 4.9x. |
| What is the current EV/EBITDA multiple of Veracyte? | Current EBITDA multiple of Veracyte is 23.6x. |
| What is the current revenue growth of Veracyte? | Veracyte revenue growth between 2023 and 2024 was 23%. |
| Is Veracyte profitable? | Yes, Veracyte is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
